Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDAllogene Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 7 | -$0.39 | -$0.25 | -$0.33 |
| Q2 2025 | 3 | -$0.33 | -$0.33 | -$0.33 |
| Q3 2025 | 6 | -$0.33 | -$0.33 | -$0.33 |
| Q4 2025 | 5 | -$0.33 | -$0.33 | -$0.33 |
| Q1 2026 | 4 | -$0.19 | -$0.19 | -$0.19 |
| Q2 2026 | 3 | -$0.19 | -$0.19 | -$0.19 |
| Q3 2026 | 2 | -$0.20 | -$0.20 | -$0.20 |
| Q4 2026 | 2 | -$0.20 | -$0.20 | -$0.20 |
Allogene Therapeutics, Inc. Earnings Date And Information
Allogene Therapeutics, Inc. last posted its earnings results on Thursday, November 7th, 2024. The company reported $-0.27 earnings per share for the quarter, topping analysts' consensus estimates of $-0.34 by $0.07. The company had revenue of 0 for the quarter and had revenue of 95,000 for the year. Allogene Therapeutics, Inc. has generated $-2 earnings per share over the last year ($-2.09 diluted earnings per share) and currently has a price-to-earnings ratio of -1.39. Allogene Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 12th, 2025 based on prior year's report dates.
Allogene Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/07/2024 | Q3 2024 | -$0.34 | -$0.32 | 0.02 | $10,769 | $0 |
| 08/07/2024 | Q2 2024 | -$0.35 | -$0.35 | 0 | $2.01 M | $0 |
| 05/13/2024 | Q1 2024 | -$0.38 | -$0.38 | 0 | N/A | $22,000 |
| 03/14/2024 | Q4 2023 | -$0.47 | -$0.51 | -0.04 | N/A | $21,000 |
| 11/02/2023 | Q3 2023 | -$0.53 | -$0.37 | 0.16 | $14,462 | $43,000 |
| 08/02/2023 | Q2 2023 | -$0.59 | -$0.53 | 0.06 | $13,467 | $44,000 |
| 05/03/2023 | Q1 2023 | -$0.63 | -$0.68 | -0.05 | N/A | $52,000 |
| 03/14/2024 | Q4 2022 | -$0.47 | -$0.65 | -0.18 | N/A | $47,000 |
| 11/02/2022 | Q3 2022 | -$0.62 | -$0.58 | 0.04 | $12,385 | $49,000 |
| 08/09/2022 | Q2 2022 | -$0.61 | -$0.52 | 0.09 | $8,333 | $86,000 |
| 05/04/2022 | Q1 2022 | -$0.59 | -$0.56 | 0.03 | N/A | $61,000 |
| 02/23/2022 | Q4 2021 | -$0.61 | -$0.54 | 0.07 | N/A | $51,000 |
| 11/04/2021 | Q3 2021 | -$0.56 | -$0.57 | -0.01 | $263,857 | $49,000 |
| 08/04/2021 | Q2 2021 | -$0.55 | -$0.53 | 0.02 | $13.92 M | $44,000 |
| 05/05/2021 | Q1 2021 | -$0.48 | -$0.25 | 0.23 | N/A | $38.35 M |
| 02/25/2021 | Q4 2020 | -$0.56 | -$0.53 | 0.03 | N/A | $0 |
| 11/04/2020 | Q3 2020 | -$0.55 | -$0.52 | 0.03 | N/A | $0 |
| 08/05/2020 | Q2 2020 | -$0.55 | -$0.53 | 0.02 | N/A | $0 |
| 05/06/2020 | Q1 2020 | -$0.57 | -$0.50 | 0.07 | N/A | $0 |
| 02/27/2020 | Q4 2019 | -$0.69 | -$0.58 | 0.11 | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Allogene Therapeutics, Inc. Earnings: FAQ's
Allogene Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 12th, 2025 based offlast year's report dates.
In the previous quarter, Allogene Therapeutics, Inc. (:ALLO) reported $-0.27 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.34 by $0.07.
The conference call for Allogene Therapeutics, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Allogene Therapeutics, Inc.'s latest earnings report can be read online.
Allogene Therapeutics, Inc. (:ALLO) has a recorded annual revenue of $95,000.
Allogene Therapeutics, Inc. (:ALLO) has a recorded net income of $-327,265,000.Allogene Therapeutics, Inc. has generated $-2.09 earnings per share over the last four quarters.
Allogene Therapeutics, Inc. (:ALLO) has a price-to-earnings ratio of -1.39 and price/earnings-to-growth ratio is -0.45.